已收盤 01-30 16:00:00 美东时间
-0.360
-2.10%
今日重点评级关注:HC Wainwright & Co.:维持Soleno Therapeutics"买入"评级,目标价从110美元升至120美元;富国银行:维持Soleno Therapeutics"超配"评级,目标价从106美元升至114美元
01-21 11:42
Longleaf Partners Small-Cap Fund (LLSCX) reported a 7.56% total return, compared with 12.81% for the Russell 2000 and 17.15% for the Russell 3000. During 2025, the fund added new positions in Shenando...
01-21 00:13
Truist Securities analyst Michael Roxland initiates coverage on Clearwater Paper (NYSE:CLW) with a Hold rating and announces Price Target of $21.
01-20 20:43
今日重点评级关注:HC Wainwright & Co.:维持Unicycive Therapeutics"买入"评级,目标价从9美元升至22美元;花旗:维持Arcus Biosciences"买入"评级,目标价从54美元升至56美元
2025-10-30 14:22
RBC Capital analyst Matthew McKellar maintains Clearwater Paper (NYSE:CLW) with a Outperform and lowers the price target from $33 to $30.
2025-10-30 00:39
Clearwater Paper Corp : RBC Cuts Target Price to $30 From $33
2025-10-29 13:18
Clearwater Paper Corp ( ($CLW) ) has released its Q3 earnings. Here is a breakd...
2025-10-29 12:34
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Clearwater Paper业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **Q3 2025核心财务表现:** - **营收**:净销售额3.99亿美元,同比增长1%,环比增长2% - **调整后EBITDA**:1,800万美元,位于指导区间1,000-2,000万美元的高端 - **净亏损**:持续经营业务净亏损5,400万美元,每股亏损3.34美元 - **现金流**:经营现金流3,400万美元,自由现金流350万美元 - **SG&A费用率**:占净销售额6.2%,处于目标区间6%-7%的低端 **年度累计表现:** -
2025-10-29 12:14
Earnings Call Insights: Clearwater Paper Corporation (CLW) Q3 2025 Management View CEO Arsen Kitch reported that "we delivered adjusted EBITDA of $18 million, which is towards the high end of our guid...
2025-10-29 07:12